Vastagbélrák: vizsgálatok itt: Lengyelország

In Lengyelország 35 Also abroad 1930

35 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.

1. fázisTaking people
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Where
Cracow, Gdansk, Poznan, Warsaw
Életkor
18 év and over
People
542 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT04929223 · EU 2023-505163-37-00
3. fázisTaking people
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
Where
Gdansk, Olsztyn, Otwock, Rzeszów, Warsaw
Életkor
18 év and over
People
900 worldwide
Run by
Summit Therapeutics
See details and how to joinNCT07228832
3. fázisTaking people
A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
Where
Cracow, Gdansk, Lodz
Életkor
18 év and over
People
1020 worldwide
Run by
EMD Serono Research & Development Institute, Inc.
See details and how to joinNCT07549412 · EU 2025-524648-37-00
3. fázisTaking people
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Where
Gliwice, Koszalin, Poznan, Rzeszów, Warsaw
Életkor
18 év and over
People
477 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06997497 · EU 2024-517232-22-00
3. fázisTaking people
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
Where
Bialystok, Brzozów, Gdansk, Gliwice, Lodz, Olsztyn, Opole, Warsaw
Életkor
18 év and over
People
1000 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06662786 · EU 2024-513852-13-00
3. fázisTaking people
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Where
Biala Podlaska, Bialystok, Brzozów, Gdansk, Lodz, Olsztyn, Opole, Warsaw
Életkor
18 év and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT06750094 · EU 2024-513853-66-00
1/2. fázisTaking people
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Where
Krakow, Lódz, Szczecin
Életkor
18 év and over
People
160 worldwide
Run by
Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00
3. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Where
Siedlce, Warsaw
Életkor
18 év and over
People
700 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07284849 · EU 2025-523735-19-00
3. fázisNot yet taking people in Lengyelország
Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.
Where
Bydgoszcz, Cracow, Opole, Poznan, Siedlce, Skorzewo, Warsaw, Wroclaw
Életkor
18 év and over
People
450 worldwide
Run by
Genmab A/S
See details and how to join2026-525883-17-00 · EU 2026-525883-17-00
1/2. fázisTaking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Cracow, Lodz, Rzeszów, Siedlce, Skorzewo
Életkor
18 év and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
2/3. fázisTaking people
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
Where
Brzozów, Cracow, Gdansk, Gliwice, Jelenia Góra, Koszalin, Opole, Warsaw, Wieliszew
Életkor
18 év and over
People
990 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07221357 · EU 2025-523224-45-00
2. fázisTaking people
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Where
Bialystok, Krakow, Lodz, Opole, Otwock, Przemyśl, Siedlce, Skórzewo, Warsaw, Wroclaw
Életkor
18 év and over
People
140 worldwide
Run by
Vividion Therapeutics, Inc.
See details and how to joinNCT07811193 · EU 2026-525507-26-00
1/2. fázisTaking people
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Where
Brzozów, Koszalin, Warsaw
Életkor
18 év and over
People
346 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06885034
3. fázisTaking people
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
Where
Gdansk, Gliwice, Olsztyn, Opole, Otwock, Poznan, Rzeszów, Warsaw
Életkor
18 év and over
People
230 worldwide
Run by
Summit Therapeutics Inc.
See details and how to join2025-521587-35-00 · EU 2025-521587-35-00
3. fázisTaking people
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Where
Cracow, Katowice, Koszalin, Opole, Poznan
Életkor
18 év and over
People
800 worldwide
Run by
Pfizer
See details and how to joinNCT07222800 · EU 2025-523521-18-00
3. fázisTaking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Bydgoszcz, Warsaw
Életkor
18 év and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
1. fázisTaking people
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Where
Bydgoszcz, Gdansk, Otwock, Poznan, Wroclaw
Életkor
18 év and over
People
1394 worldwide
Run by
Exelixis
See details and how to joinNCT05176483 · EU 2023-510061-10-00
2. fázisTaking people
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Where
Cracow, Gliwice, Warsaw
Életkor
18 év to 130 év
People
454 worldwide
Run by
AstraZeneca
See details and how to joinNCT05489211 · EU 2023-509436-26-00
No phaseTaking people
A Study of Fruquintinib in Adults With Metastatic Colorectal Cancer in Poland
Where
Bialystok, Bydgoszcz, Gliwice, Krakow, Lublin, Opole, Poznan, Przemyśl, Szczecin, Warsaw
Életkor
18 év and over
People
110
Run by
Takeda
See details and how to joinNCT07623174
3. fázisTaking people
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation
Where
Gdynia, Kielce, Lodz, Opole, Poznan, Warsaw
Életkor
18 év and over
People
450 worldwide
Run by
Amgen
See details and how to joinNCT06252649
1. fázisTaking people
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
Where
Bydgoszcz, Otwock, Warsaw
Életkor
18 év and over
People
40
Run by
Molecure S.A.
See details and how to joinNCT05759923 · EU 2024-510836-31-00
3. fázisTaking people
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Cancer With KRAS p.G12C Mutation (CodeBreaK 301)
Where
Gdynia, Kielce, Lodz, Opole, Poznan, Szczecin, Warsaw
Életkor
18 év to 64 év
People
241 worldwide
Run by
Amgen Inc.
See details and how to join2022-502352-31-00 · EU 2022-502352-31-00
3. fázisTaking people
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
Where
Gdansk, Konin, Lodz, Rzeszów, Warsaw
Életkor
18 év and over
People
400 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05253651 · EU 2024-514180-25-00
No phaseTaking people
Active Surveillance vs Adjuvant Chemoradiotherapy for Locally Resected Intermediate-Risk T1 Rectal Cancer
Where
Gdansk, Warsaw
Életkor
18 év and over
People
480 worldwide
Run by
Medical University of Gdansk
See details and how to joinNCT07669298
1/2. fázisTaking people
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Where
Gdansk, Warsaw
Életkor
12 év and over
People
500 worldwide
Run by
Turning Point Therapeutics, Inc.
See details and how to joinNCT03093116 · EU 2024-512606-25-00